E
Kyverna Therapeutics, Inc. KYTX
$1.98 $0.010.51%
Recommendation
Sell
Prev Close
$1.98
Volume
334,576
Avg Vol (90D)
365,058
Market Cap
$85.57M
Dividend & Yield
--
52-Week Range
$1.86 - $24.91
P/E (TTM)
--
EPS (TTM)
-$3.46
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
HC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00
4/5/2025 - MarketBeat
Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
4/3/2025 - TipRanks Financial Blog
Kyverna Therapeutics price target lowered by $2 at H.C. Wainwright, here's why
4/3/2025 - The Fly
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from Analysts
4/2/2025 - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Given New $20.00 Price Target at Morgan Stanley
4/2/2025 - MarketBeat
Kyverna Therapeutics price target lowered by $20 at Morgan Stanley, here's why
4/1/2025 - The Fly
ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)
3/31/2025 - Globe Newswire
Kyverna Therapeutics price target lowered to $12 from $13 at UBS
3/29/2025 - TipRanks Financial Blog
Kyverna Therapeutics price target lowered by $1 at UBS, here's why
3/29/2025 - The Fly
Kyverna Therapeutics Advances CAR T-Cell Therapy Trials
3/29/2025 - TipRanks Financial Blog
Kyverna Therapeutics (NASDAQ:KYTX) Issues Earnings Results, Misses Estimates By $0.01 EPS
3/28/2025 - MarketBeat
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 ...
3/27/2025 - GuruFocus
Kyverna Therapeutics Inc (KYTX) Reports Q4 2024 Net Loss Per Share of $3. ...
3/27/2025 - GuruFocus
Kyverna Therapeutics files $250M mixed securities shelf
3/27/2025 - The Fly
Kyverna Therapeutics sees cash and securities sufficient into 2027
3/27/2025 - TipRanks Financial Blog
Kyverna Therapeutics sees cash and securities sufficient into 2027
3/27/2025 - The Fly
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
3/27/2025 - PR Newswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf
3/24/2025 - Globe Newswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf
3/21/2025 - Globe Newswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf
3/18/2025 - Globe Newswire
Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday
3/18/2025 - MarketBeat
Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf
3/17/2025 - Globe Newswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
3/13/2025 - Globe Newswire
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
3/3/2025 - GuruFocus
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
3/3/2025 - PR Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$141.42M
EBIT (TTM)
-$142.60M
Net Income (TTM)
-$127.48M
Balance Sheet
Total Assets (Q)
$304.65M
Total Debt (Q)
$8.24M
Total Liabilities (Q)
$38.06M
Book Value Per Share (Q)
$6.17
Cash Flow
Cash from Operations (TTM)
-$114.25M
Cash from Investing (TTM)
-$160.90M
Cash from Financing (TTM)
$337.11M
Net Change in Cash (TTM)
$61.96M
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-15.92%
30-Day Total Return
-31.72%
60-Day Total Return
-47.89%
90-Day Total Return
-54.90%
Year to Date Total Return
-49.49%
1-Year Total Return
-91.09%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $1.86
52-week High
Apr 10, 2024 - $24.91
Valuation
Market Cap
$85.57M - Micro Cap
Enterprise Value
-$192.17M
Price/Sales (TTM)
--
Price/Book (Q)
0.32
Dividends and Shares
Shares Outstanding
43.23M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
kyvernatx.com
Phone Number
(510) 925-2492
Address
5980 Horton Street
Emeryville, CA 94608
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company’s lead product candidate is KYV-101... more
NASDAQ 04/04/2025 4:00PM Eastern Quotes delayed
Weiss Ratings